Clinical Trial Update: A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer [Phase 2]

View source ↗

Summary

A Phase II trial evaluating chemoradiotherapy with nimotuzumab for unresectable esophageal cancer has completed, reporting results from the study sponsored by t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Esophageal Cancer, Chemoradiotherapy | Phase 2 | Status: COMPLETED